This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock VACC vs. NLTX, BIOA, CYBN, VIRI, WHWK, ELYM, OSTX, ATNM, NBRV, and AADIShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Eliem Therapeutics (ELYM), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), and Aadi Bioscience (AADI). Vaccitech vs. Its Competitors Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Eliem Therapeutics OS Therapies Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Neoleukin Therapeutics (NASDAQ:NLTX) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings. Does the media refer more to NLTX or VACC? In the previous week, Neoleukin Therapeutics had 1 more articles in the media than Vaccitech. MarketBeat recorded 1 mentions for Neoleukin Therapeutics and 0 mentions for Vaccitech. Neoleukin Therapeutics' average media sentiment score of 0.75 beat Vaccitech's score of 0.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neoleukin Therapeutics Positive Vaccitech Neutral Is NLTX or VACC more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Vaccitech -409.18%-23.41%-20.85% Do institutionals and insiders have more ownership in NLTX or VACC? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 26.1% of Vaccitech shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 6.0% of Vaccitech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, NLTX or VACC? Vaccitech has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.19Vaccitech$13.42M3.30$5.34M-$1.43-0.80 Which has more risk and volatility, NLTX or VACC? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. SummaryVaccitech beats Neoleukin Therapeutics on 7 of the 12 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.33M$873.83M$5.76B$10.03BDividend YieldN/A4.84%5.28%4.52%P/E Ratio-0.801.1475.4326.15Price / Sales3.3026.52515.98171.98Price / Cash19.3019.5637.2059.76Price / Book0.186.7711.536.20Net Income$5.34M-$4.20M$3.28B$270.56M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$1.15-5.4%N/A-5.1%$44.33M$13.42M-0.8033NLTXNeoleukin TherapeuticsN/A$19.87+1.2%N/A-44.4%$186.74MN/A-6.3990High Trading VolumeBIOABioAge LabsN/A$4.63-2.3%N/AN/A$165.99MN/A0.00N/APositive NewsCYBNCybin2.5295 of 5 stars$6.29+4.6%$85.00+1,252.4%N/A$148.78MN/A-1.4450VIRIVirios TherapeuticsN/A$4.81-3.0%$5.00+3.9%+2,607.2%$92.63MN/A-17.825Gap DownWHWKWhitehawk TherapeuticsN/A$1.82+0.6%N/AN/A$85.78M$25.98M-30.3340ELYMEliem TherapeuticsN/A$2.23flatN/A-68.5%$66.35MN/A-4.219OSTXOS Therapies1.8244 of 5 stars$2.06-1.9%$18.00+773.8%-47.5%$65.03MN/A-2.60N/AATNMActinium Pharmaceuticals2.4888 of 5 stars$1.69-1.2%$4.50+166.3%-12.6%$52.72MN/A-1.2230Short Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.81-0.5%N/A-1.1%$44.70M$25.07M-0.7940News CoverageGap Down Related Companies and Tools Related Companies Neoleukin Therapeutics Competitors BioAge Labs Competitors Cybin Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors Eliem Therapeutics Competitors OS Therapies Competitors Actinium Pharmaceuticals Competitors Nabriva Therapeutics Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VACC Stock Alerts